Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

A novel system enhancing the endosomal escapes of peptides promotes Bak BH3 peptide inducing apoptosis in lung cancer A549 cells.

Lin N, Zheng W, Li L, Liu H, Wang T, Wang P, Ma X.

Target Oncol. 2014 Jun;9(2):163-70. doi: 10.1007/s11523-013-0282-9. Epub 2013 Jun 6.

PMID:
23740403
2.

Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide.

Sugita T, Yoshikawa T, Mukai Y, Yamanada N, Imai S, Nagano K, Yoshida Y, Shibata H, Yoshioka Y, Nakagawa S, Kamada H, Tsunoda S, Tsutsumi Y.

Biochem Biophys Res Commun. 2007 Nov 30;363(4):1027-32. Epub 2007 Sep 29.

PMID:
17923117
3.

Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis.

Orzechowska EJ, Kozlowska E, Czubaty A, Kozlowski P, Staron K, Trzcinska-Danielewicz J.

BMC Cancer. 2014 Oct 18;14:771. doi: 10.1186/1471-2407-14-771.

4.

Oligopeptides derived from autophosphorylation sites of EGF receptor suppress EGF-stimulated responses in human lung carcinoma A549 cells.

Kuroda Y, Kato-Kogoe N, Tasaki E, Murata E, Ueda K, Abe M, Miyamoto K, Nakase I, Futaki S, Tohyama Y, Hirose M.

Eur J Pharmacol. 2013 Jan 5;698(1-3):87-94. doi: 10.1016/j.ejphar.2012.10.007. Epub 2012 Oct 17.

PMID:
23085023
5.

Targeted proapoptotic LHRH-BH3 peptide.

Dharap SS, Minko T.

Pharm Res. 2003 Jun;20(6):889-96.

PMID:
12817893
6.

BH3-based fusion artificial peptide induces apoptosis and targets human colon cancer.

Liu Y, Li Y, Wang H, Yu J, Lin H, Xu D, Wang Y, Liang A, Liang X, Zhang X, Fu M, Qian H, Lin C.

Mol Ther. 2009 Sep;17(9):1509-16. doi: 10.1038/mt.2009.43. Epub 2009 Apr 7.

7.

Amphipathic tail-anchoring peptide and Bcl-2 homology domain-3 (BH3) peptides from Bcl-2 family proteins induce apoptosis through different mechanisms.

Ko JK, Choi KH, Peng J, He F, Zhang Z, Weisleder N, Lin J, Ma J.

J Biol Chem. 2011 Mar 18;286(11):9038-48. doi: 10.1074/jbc.M110.198457. Epub 2010 Dec 28.

8.

Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002.

Uchida T, Kanazawa T, Takashima Y, Okada H.

Chem Pharm Bull (Tokyo). 2011;59(2):196-201.

9.

Targeted delivery of ubiquitin-conjugated BH3 peptide-based Mcl-1 inhibitors into cancer cells.

Muppidi A, Doi K, Edwardraja S, Pulavarti SV, Szyperski T, Wang HG, Lin Q.

Bioconjug Chem. 2014 Feb 19;25(2):424-32. doi: 10.1021/bc4005574. Epub 2014 Jan 22.

10.

Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins.

Moreau C, Cartron PF, Hunt A, Meflah K, Green DR, Evan G, Vallette FM, Juin P.

J Biol Chem. 2003 May 23;278(21):19426-35. Epub 2003 Mar 17.

11.

Organelle-targeted delivery of biological macromolecules using the protein transduction domain: potential applications for Peptide aptamer delivery into the nucleus.

Yoshikawa T, Sugita T, Mukai Y, Yamanada N, Nagano K, Nabeshi H, Yoshioka Y, Nakagawa S, Abe Y, Kamada H, Tsunoda S, Tsutsumi Y.

J Mol Biol. 2008 Jul 25;380(5):777-82. doi: 10.1016/j.jmb.2008.05.047. Epub 2008 May 29.

PMID:
18571668
12.
13.
14.

HIV-TAT-fused FHIT protein functions as a potential pro-apoptotic molecule in hepatocellular carcinoma cells.

Yu GR, Qin WW, Li JP, Hua W, Meng YL, Chen R, Yan B, Wang L, Zhang X, Jia LT, Zhao J, Zhang R, Yang AG.

Biosci Rep. 2012 Jun;32(3):271-9. doi: 10.1042/BSR20110033.

PMID:
21679157
15.

The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.

Cao X, Yap JL, Newell-Rogers MK, Peddaboina C, Jiang W, Papaconstantinou HT, Jupitor D, Rai A, Jung KY, Tubin RP, Yu W, Vanommeslaeghe K, Wilder PT, MacKerell AD Jr, Fletcher S, Smythe RW.

Mol Cancer. 2013 May 16;12(1):42. doi: 10.1186/1476-4598-12-42.

16.

Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions.

Finnegan NM, Curtin JF, Prevost G, Morgan B, Cotter TG.

Br J Cancer. 2001 Jul 6;85(1):115-21.

17.

Novel RasGRF1-derived Tat-fused peptides inhibiting Ras-dependent proliferation and migration in mouse and human cancer cells.

Sacco E, Metalli D, Spinelli M, Manzoni R, Samalikova M, Grandori R, Morrione A, Traversa S, Alberghina L, Vanoni M.

Biotechnol Adv. 2012 Jan-Feb;30(1):233-43. doi: 10.1016/j.biotechadv.2011.05.011. Epub 2011 May 18.

PMID:
21620943
18.

A TAT-streptavidin fusion protein directs uptake of biotinylated cargo into mammalian cells.

Albarran B, To R, Stayton PS.

Protein Eng Des Sel. 2005 Mar;18(3):147-52. Epub 2005 Apr 8.

19.

Fusion of HIV-1 Tat protein transduction domain to poly-lysine as a new DNA delivery tool.

Hashida H, Miyamoto M, Cho Y, Hida Y, Kato K, Kurokawa T, Okushiba S, Kondo S, Dosaka-Akita H, Katoh H.

Br J Cancer. 2004 Mar 22;90(6):1252-8.

20.

Enhanced targeted anticancer effects and inhibition of tumor metastasis by the TMTP1 compound peptide TMTP1-TAT-NBD.

Liu R, Xi L, Luo D, Ma X, Yang W, Xi Y, Wang H, Qian M, Fan L, Xia X, Li K, Wang D, Zhou J, Meng L, Wang S, Ma D.

J Control Release. 2012 Aug 10;161(3):893-902. doi: 10.1016/j.jconrel.2012.05.002. Epub 2012 May 11.

PMID:
22580115
Items per page

Supplemental Content

Write to the Help Desk